REG - Goldman Sachs (EPT) Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Amendment
RNS Number : 9784LGoldmanSachs International02 January 2019Amendment - due to the amendment of Derivative transactions, the disclosure made on 13 November for dealings on 12 November has been updated. Sections 2(b) have been updated.
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
(GS) GOLDMAN SACHS INTERNATIONAL
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(c) Name of the party to the offer with which exempt principal trader is connected:
SHIRE PLC
(d) Date dealing undertaken:
12 November 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - disclosed previously for SHIRE PLC
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/ sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
Purchases
615,479
4,563.0000 JPY
4,485.0000 JPY
Ordinary
Sales
1,091,584
4,563.0000 JPY
4,490.5000 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
Increasing a long position
600
4,500.0000 JPY
Ordinary
CFD
Increasing a short position
100
4,528.5400 JPY
Ordinary
CFD
Opening a long position
11,194
4,533.7007 JPY
Ordinary
SWAP
Increasing a long position
133,175
4,521.5107 JPY
Ordinary
SWAP
Increasing a long position
64,610
4,521.5107 JPY
Ordinary
SWAP
Increasing a long position
10,045
4,521.5107 JPY
Ordinary
SWAP
Increasing a long position
142,170
4,521.5107 JPY
Ordinary
SWAP
Opening a long position
167,800
4,532.8029 JPY
Ordinary
SWAP
Opening a long position
4,139
4,533.3200 JPY
Ordinary
SWAP
Opening a long position
25,861
4,533.3200 JPY
Ordinary
SWAP
Reducing a short position
3,448
4,547.6924 JPY
Ordinary
SWAP
Reducing a short position
2,672
4,547.6924 JPY
Ordinary
SWAP
Reducing a short position
428
4,547.6924 JPY
Ordinary
SWAP
Reducing a short position
552
4,547.6924 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
Ordinary
Call Option
Selling
499,600
5,242.1341 JPY
EUROPEAN
13/06/2019
106.1828 JPY
Ordinary
Call Option
Selling
499,600
5,242.1341 JPY
EUROPEAN
13/06/2019
106.1828 JPY
Ordinary
Put Option
Purchasing
499,600
3,874.6209 JPY
EUROPEAN
13/06/2019
117.8249 JPY
Ordinary
Put Option
Purchasing
499,600
3,874.6209 JPY
EUROPEAN
13/06/2019
117.8249 JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising / exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
NONE
Date of disclosure:
02 January 2019
Contact name:
Kashif Rafiq and Papa Lette
Telephone number:
+44(20) 7051 0547 / +44(20) 7774 7442
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFERUGUPCGUPBGPP
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement